Notice of Allowability	Application No.	Applicant(s)		
	09/752,724	KITAKAZE, MASAF	KITAKAZE, MASAFUMI	
	Examiner	Art Unit		
	Rita Mitra	1653		
The MAILING DATE of this communication apperature All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHT of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED or other appropriate comm IGHTS. This application is	in this application. If not includ nunication will be mailed in due	ed course. THIS	
1. This communication is responsive to <u>12/16/2004</u> .				
2. The allowed claim(s) is/are 6-16.				
3. \boxtimes The drawings filed on <u>03 January 2001</u> are accepted by th	e Examiner.			
 4. Acknowledgment is made of a claim for foreign priority una) All b) Some* c) None of the: Certified copies of the priority documents have Certified copies of the priority documents have Copies of the certified copies of the priority do International Bureau (PCT Rule 17.2(a)). * Certified copies not received: 	been received. been received in Applicat	ion No	ition from the	
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONN THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.	of this communication to fi IENT of this application.	le a reply complying with the re	quirements	
5. A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which give			NOTICE OF	
6. CORRECTED DRAWINGS (as "replacement sheets") must (a) including changes required by the Notice of Draftspers 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner' Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in the second of the sheet in the second of the sheet.	son's Patent Drawing Revie s Amendment / Comment on .84(c)) should be written on	or in the Office action of the drawings in the front (not the	e back) of	
7. DEPOSIT OF and/or INFORMATION about the depo attached Examiner's comment regarding REQUIREMENT			Note the	
Attaches and a				
Attachment(s) 1. ☐ Notice of References Cited (PTO-892)	5. Notice of	Informal Patent Application (PT	O-152)	
2. \square Notice of Draftperson's Patent Drawing Review (PTO-948)		Summary (PTO-413), o./Mail Date		
3. Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date		s Amendment/Comment		
4. Examiner's Comment Regarding Requirement for Deposit	8. 🛛 Examiner'	s Statement of Reasons for Alle	owance	
of Biological Material	9. 🗌 Other	·		

Art Unit: 1653

DETAILED ACTION

Status of the Claims

Applicants' Request for Continued Examination (RCE) under 37 C.F.R. 1.114 and an amendment and reply in response to office action dated January 16, 2004, filed on December 16, 2004, is acknowledged. Claims 1-5 have been canceled. Claims 6, 7 and 11 have been amended. Therefore, claims 6-16 are currently pending.

Response to Amendments and Remarks

Claim Rejections - 35 USC § 102

Rejection of claims 6-16 are withdrawn in view of amendments to claims 6, 7 and 11.

An Examiner's Amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Examiner's Amendments to the Specification:

On page 19 (abstract page), the title "Treatment or Prophylaxis of Ischemic Heart Disease" has been deleted.

Reasons for Allowance

The following is an examiner's statement of reasons for allowance:

The prior art of record does not teach or suggest a method of treatment of ischemic heart disease, comprising administration to a patient a composition comprising a substance, as an active ingredient, which can increase intracellular cGMP production by acting on a natriuretic peptide receptor, and which has the effect of reducing an infarct region during ischemia reperfusion therapy, wherein the substance as an active ingredient is a natriuretic peptide

Application/Control Number: 09/752,724 Page 3

Art Unit: 1653

comprising atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) or C-type natriuretic peptide (CNP). Thus the method of reducing an infarct region and ischemia reperfusion injury in the treatment of ischemic heart disease of the instant application is novel.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

Claims 6-16 are allowed.

Inquiries

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Rita Mitra whose telephone number is (571) 272-0954. The Examiner can normally be reached from 9:30 a.m. to 6:30 p.m. on weekdays. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Dr. Jon Weber, can be reached at (571) 272-0925. Papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax Center. The faxing of such papers must conform with the notice published in the Official Gazette,1096 OG 30 (November 15, 1989). The Fax Center number is (703) 872-9306. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (571) 272-0547.

Rita Mitra, Ph.D.

March 4, 2005

JON WEBER

SUPERVISORY PATENT EXAMINER